BioLineRx (NASDAQ:BLRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRXFree Report) in a research report report published on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 25th.

Read Our Latest Stock Report on BioLineRx

BioLineRx Price Performance

BLRX stock opened at $0.14 on Friday. BioLineRx has a 52 week low of $0.14 and a 52 week high of $1.52. The firm has a market capitalization of $11.42 million, a P/E ratio of -0.65 and a beta of 1.46. The company has a fifty day simple moving average of $0.29 and a two-hundred day simple moving average of $0.51. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BLRX. PVG Asset Management Corp bought a new stake in shares of BioLineRx in the 2nd quarter worth about $70,000. Atria Investments Inc raised its position in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the period. Finally, CVI Holdings LLC bought a new stake in BioLineRx in the second quarter worth about $462,000. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Featured Articles

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.